Abstract
The goal of this article is to discuss ways to further improve the search for potentially procognitive agents that could be used to enhance cognition and functional outcome in schizophrenia. In particular, we focus on the potential advantages to this process of using a contemporary, cognitive neuroscience-based approach to measuring cognitive function in clinical trials of procognitive agents in schizophrenia. These tools include computer-administered tasks that measure specific cognitive systems (such as attention, working memory, long-term memory, cognitive control) as well as the component cognitive processes that comprise these more overarching systems. The advantages of using these tools include the ability to identify and use homologous animal and human models in the drug discovery and testing process and the ability to incorporate noninvasive functional imaging measures into clinical trial contexts at several different phases of the drug development process. However, despite the clear potential advantages to using such methods, a number of barriers exist to their translation from basic science tools to tools for drug discovery. We discuss the development and implementation of a new project, Cognitive Neuroscience Treatment to Improve Cognition in Schizophrenia, designed to identify and overcome these barriers to the translation of cognitive neuroscience measures and methods into regular use in the drug discovery and development process of cognition-enhancing agents for use in schizophrenia.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1131-1137 |
| Number of pages | 7 |
| Journal | Schizophrenia Bulletin |
| Volume | 33 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 2007 |
Fingerprint
Keywords
- Cognitive
- Imaging
- Pharmacology
ASJC Scopus subject areas
- Psychiatry and Mental health
- Neuroscience(all)
Cite this
Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia : The CNTRICS initiative. / Carter, Cameron S; Barch, Deanna M.
In: Schizophrenia Bulletin, Vol. 33, No. 5, 09.2007, p. 1131-1137.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia
T2 - The CNTRICS initiative
AU - Carter, Cameron S
AU - Barch, Deanna M.
PY - 2007/9
Y1 - 2007/9
N2 - The goal of this article is to discuss ways to further improve the search for potentially procognitive agents that could be used to enhance cognition and functional outcome in schizophrenia. In particular, we focus on the potential advantages to this process of using a contemporary, cognitive neuroscience-based approach to measuring cognitive function in clinical trials of procognitive agents in schizophrenia. These tools include computer-administered tasks that measure specific cognitive systems (such as attention, working memory, long-term memory, cognitive control) as well as the component cognitive processes that comprise these more overarching systems. The advantages of using these tools include the ability to identify and use homologous animal and human models in the drug discovery and testing process and the ability to incorporate noninvasive functional imaging measures into clinical trial contexts at several different phases of the drug development process. However, despite the clear potential advantages to using such methods, a number of barriers exist to their translation from basic science tools to tools for drug discovery. We discuss the development and implementation of a new project, Cognitive Neuroscience Treatment to Improve Cognition in Schizophrenia, designed to identify and overcome these barriers to the translation of cognitive neuroscience measures and methods into regular use in the drug discovery and development process of cognition-enhancing agents for use in schizophrenia.
AB - The goal of this article is to discuss ways to further improve the search for potentially procognitive agents that could be used to enhance cognition and functional outcome in schizophrenia. In particular, we focus on the potential advantages to this process of using a contemporary, cognitive neuroscience-based approach to measuring cognitive function in clinical trials of procognitive agents in schizophrenia. These tools include computer-administered tasks that measure specific cognitive systems (such as attention, working memory, long-term memory, cognitive control) as well as the component cognitive processes that comprise these more overarching systems. The advantages of using these tools include the ability to identify and use homologous animal and human models in the drug discovery and testing process and the ability to incorporate noninvasive functional imaging measures into clinical trial contexts at several different phases of the drug development process. However, despite the clear potential advantages to using such methods, a number of barriers exist to their translation from basic science tools to tools for drug discovery. We discuss the development and implementation of a new project, Cognitive Neuroscience Treatment to Improve Cognition in Schizophrenia, designed to identify and overcome these barriers to the translation of cognitive neuroscience measures and methods into regular use in the drug discovery and development process of cognition-enhancing agents for use in schizophrenia.
KW - Cognitive
KW - Imaging
KW - Pharmacology
UR - http://www.scopus.com/inward/record.url?scp=34548348724&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548348724&partnerID=8YFLogxK
U2 - 10.1093/schbul/sbm081
DO - 10.1093/schbul/sbm081
M3 - Article
C2 - 17630405
AN - SCOPUS:34548348724
VL - 33
SP - 1131
EP - 1137
JO - Schizophrenia Bulletin
JF - Schizophrenia Bulletin
SN - 0586-7614
IS - 5
ER -